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such as HMGB1. Donor T cell analyses demonstrated
signiﬁcantly greater expansion of activated CD69+, Th1
(IFN-g+) and Th17 (IL-17A+) cells in the spleen and in the
GVHD target organs, namely liver and gut (P<0.05).
Enhanced GVHD mortality and severity was observed in
multiple irradiated BMT models (MHC-matched multiple
minor antigen mismatched C3H.sw->B6 and haploidentical
B6->F1 models). We performed detailed phenotypic analysis
of various T cell subsets in naïve Siglec-G-/- and WT B6
animals and found similar distribution of naïve, memory,
effector and regulatory T cells suggesting that alteration in
T-cell subsets in the donor T-cell inoculumwas not the cause
for increase in GVHD. Functional analyses of naïve Siglec-G-/-
T cells, showed similar proliferation in vitro after stimulation
with allogeneic DCs or CD3/CD28 antibody stimulationwhen
compared toWT Tcells. Furthermore Siglec-G-/- Tregs as well
as WT Tregs were equally suppressive in repressing either
WT or Siglec-G-/- naïve T-cells demonstrating that Siglec-G
expression on Tregs is not critical for their suppressive
function or on naïve T-cells to be regulated by Tregs. By
contrast Siglec-G-/- T cells showed higher proliferation after
TCR stimulation (CD3/CD28) only upon with addition of
DAMP (HMGB-1) demonstrating that direct regulation of
T-cell response to DAMP by Siglec-G regulates its TCR driven
proliferative responses. Finally, in order to explore the
Siglec-G+T cells interaction with its ligand in hosts, we next
used CD24-/- BALB/c animals as hosts. CD24-/- animals also
demonstrated enhanced GVHD mortality when compared to
WT animals. Collectively, our data suggest, for the ﬁrst time
to our knowledge that Siglec-G mediated responses to
DAMPs has T-cell autonomous effects and through its
engagement with its ligand CD24 in the hosts is critical for
mitigating GVHD.46
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Tokyo, JapanBackground: Bronchiolitis obliterans syndrome (BOS) after
allogeneic hematopoietic cell transplant (HCT) is associated
with high mortality. Recently, we showed efﬁcacy for
montelukast to treat BOS. We hypothesized that FAM
(Fluticasone propionate (440 mcg inhaled bid, provided by
GlaxoSmithKline), Azithromycin (250 mg 3x/week), and
Montelukast (10mg QD, provided by Merck) for up to 6
months, with brief steroid pulse could avert progression of
new-onset BOS and tested this in a phase II, single-arm, open
label, multicenter study (NCT01307462).
Results: Thirty-six patients from 10 institutions were
enrolled within 6 months of BOS diagnosis (NIH modiﬁed
criteria: FEV1<75% predicted, FEV1/VC <0.7, and >10% FEV1
decline from pre-HSCT, absence of infection). Themedian age
was 57 years (range 23-72), 47% were females, with
moderate obstruction (median FEV1 46%; FEV1/FVC 0.5) at
enrollment. The primary endpoint was treatment success,
deﬁned as < 10% FEV1 decline at 3 months, with 60%
treatment success seen in historical controls (published
data). FAM was well tolerated with only 1 grade 4 SAE
possibly related to FAM (infection), and no patient stopped
FAM prior to 3 months. 3 month results: Eighty-three
percent (n¼30/36) had treatment success (vs. 60% in
historical controls, p¼0.004) at 3 months; 5 lacked
pulmonary function tests (PFTs), and 1 had decline.
Assuming patients without PFTs at 3 months were treatment
failures, 36% (n¼13/36) had increased FEV1 by 5% or more,
and 33% (n¼12/36) had less than 5% decline in FEV1. Steroid
exposure was reduced signiﬁcantly from a median of 0.65
mg/kg/day at enrollment to 0.31 mg/kg/day at 3 months in
evaluable patients, with only 19% receiving added
immunosuppression during that period (associated with
<20% of successes). Based on NIH calculated overall cGVHD
response, 19% had a CR or PR, while 22% had stable disease at
3 months. Patient-reported outcomes (n¼24) were better
from baseline to 3 months for SF-36 social functioning score
(p¼0.03) and mental component score (p¼0.02), FACT
emotional well-being (p¼0.03), and Lee symptom scores in
lung (p¼0.01), skin (p¼0.03), mouth (p¼0.03), and overall
summary score (p¼0.001). Six minute walk test improved by
a median of 127 feet (p¼0.02). 6 month results: 10 patients
could not be evaluated at 6 months: 1 died, 1 withdrew, 5 did
not undergo PFTs and 3 were on study < 6 months; 20/26
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S62(77%) evaluable patients had treatment success at 6 months.
Overall survival at 6 months was 97% (n¼35/36).
Conclusion: These data suggest that: FAMwaswell tolerated
and may halt pulmonary compromise in newly diagnosed
BOS and permit steroid reductions, which collectively
improve cGVHD outcomes and quality of life.Figure 1.
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Background: Chronic GVHD (cGVHD) remains the major
contributor to morbidity and mortality for survivors of
allogeneic hematopoietic cell transplant (HCT), but it
remains a clinical diagnosis.
Methods: We used a proteomics discovery approach
comparing plasma pools from onset of de novo cGVHD
(N¼17), progressive cGVHD (N¼18), and matched time-point
samples from 19 patients without GVHD. Of 105 proteins that
showed at least 1.3-fold change in the quantiﬁcation ratio,
we further selected 24 proteins based on their involvement
in relevant pathway networks, and the availability of ELISA.
In addition, two markers (CXCL9 and ST2) were measured
based on previously noted associations with cGVHD or
refractory acute GVHD.
Levels of these 26 proteins were measured by ELISA in
plasma from an independent set of 178 patients with cGVHD,
and from 33 controls without cGVHD. Logistic regressionwas
used to evaluate the association between cGVHD and
biomarkers after log transformation. All analyses were
adjusted for signiﬁcant clinical variables considering age, sex,
stem cell source, conditioning (nonmyeloablative vs. others),
donor (matched sibling vs. others), and time from HCT to
sample collection. To determine the best combinationmodel,
we used forward selectionwith a 0.05 signiﬁcance threshold,
conﬁrmed by backward selection. ROC curves were
generated for the best single biomarker, and the combination
model. The analysis of nonrelapse mortality (NRM) divided
the panel weighted sum on the median value among cGVHD
cases (N ¼ 178), and compared cases above and below the
median.
Results: Of the 26 proteins tested, 9 were associated with
cGVHD with p-values < 0.05 (Table 1). Together ST2, CXCL9,Table 1
Area under
ROC
P-value Adjusted
P-value
Combination
ST2 0.832 <0.0001 <0.0001 Yes
MMP3 0.787 <0.0001 <0.0001 Yes
TRAILR3 0.716 0.0002 0.0002
OPN 0.708 <0.0001 <0.0001 Yes
SELP 0.661 0.008 0.005
CKIT 0.654 0.007 0.01
COMP 0.643 0.009 0.002
CXCL9 0.628 0.02 0.01 Yes
CD146 0.616 0.03 0.04
Combination 0.885 <0.0001 <0.0001
Figure 3.MMP3, and OPN compose a biomarker panel for diagnosis of
cGVHD with an AUC of 0.89 (Fig 1). We next compared
the biomarker panel between groups with different
cGVHD severity (none, mild/moderate, severe) (Fig 2).
Severity of cGVHD was associated with the biomarker
panel (p<0.0001 compared to control, and p¼0.007
